réservé à la recherche

Staurosporine (STS) Inhibiteur de Protéine Kinase

N° Cat.S1421

Staurosporine (STS) est un puissant inhibiteur de PKC pour PKCα, PKCγ et PKCη avec des IC50 de 2 nM, 5 nM et 4 nM, moins puissant pour PKCδ (20 nM), PKCε (73 nM) et peu actif pour PKCζ (1086 nM) dans des essais sans cellules. Ce composé montre également des activités inhibitrices sur d'autres kinases, telles que PKA, PKG, S6K, CaMKII, etc. Phase 3.
Staurosporine (STS) Antineoplastic and Immunosuppressive Antibiotics inhibiteur Chemical Structure

Structure chimique

Poids moléculaire: 466.53

Aller à

Contrôle qualité

Lot : Pureté : 99.61%
99.61

Produits Souvent Utilisés Avec Staurosporine (STS)

Z-VAD-FMK

Z-VAD-FMK inhibits cell death induced by this compound in SJG2/MT330 cells.

Culture cellulaire, traitement et concentration de travail

Lignées cellulaires Type dessai Concentration Temps dincubation Formulation Description de lactivité PMID
human colon carcinoma cell line HCT116 Function assay Concentration required for growth inhibition of human colon carcinoma cell line HCT116, IC50=6 nM. 15537345
human PBMC Function assay 24 h Suppression of IL2 production in human PBMC after 24 hrs by ELISA, IC50=16 nM. 18585046
endothelial cells Function assay Effective dose against plasminogen activator activity stimulated by phorbol ester in endothelial cells, ED50 = 7.5 μM. 8709095
Sf9 insect cells Function assay Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells, IC50 = 0.02 μM. 9873605
LoVo cells Antiproliferative activity assay Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay, IC50 = 0.001 μM. 11591505
umbilical vein endothelial cells Antiproliferative activity assay Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay, IC50 = 0.004 μM. 11591505
ST-486 cells Antiproliferative activity assay Antiproliferative activity against burkit lymphoma cell line (ST-486 cells) using MTT assay, IC50 = 0.007 μM. 11591505
DLD-1 cells Antiproliferative activity assay Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay, IC50 = 0.009 μM. 11591505
HEK293 cells Function assay Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA, IC50 = 0.077 μM. 12941331
P19 cells Function assay Inhibition of Platelet-derived growth factor receptor in P19 cells, IC50 = 0.002 μM. 15771419
P19 cells Function assay Inhibition of Platelet-derived growth factor receptor in P19 cells, IC50 = 0.002 μM. 15771419
P19 cells Function assay Inhibition of Protein Kinase A in P19 cells, IC50 = 0.004 μM. 15771419
P19 cells Function assay Inhibition of Calcium/calmodulin-dependent protein kinase type II in P19 cells, IC50 = 0.006 μM. 15771419
P19 cells Function assay Inhibition of Cyclin-dependent kinase 1 in P19 cells, IC50 = 0.008 μM. 15771419
P19 cells Function assay Inhibition of Vascular endothelial growth factor receptor in P19 cells, IC50 = 0.014 μM. 15771419
HEK293 cells Function assay Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2, IC50 = 0.077 μM. 15771419
P19 cells Function assay Inhibition of Insulin receptor kinase in P19 cells, IC50 = 0.2 μM. 15771419
P19 cells Function assay Inhibition of Casein kinase 1 in P19 cells, IC50 = 1.4 μM. 15771419
FL5.12-Akt1 cells Antiproliferative activity assay Antiproliferative activity against FL5.12-Akt1 cells by MTT assay, IC50 = 0.29 μM. 16403626
MiaPaCa-2 cells Antiproliferative activity assay Antiproliferative activity against MiaPaCa-2 cells by MTT assay, IC50 = 0.37 μM. 16403626
FL5.12-Akt1 cells Function assay Activity against GSK3 in FL5.12-Akt1 cells, EC50 = 0.46 μM. 16403626
MiaPaCa-2 cells Antiproliferative activity assay Antiproliferative activity against human MiaPaCa-2 cells, IC50 = 0.37 μM. 16413780
FL5.12-Akt1 cells Function assay Activity against GSK3 phosphorylation in FL5.12-Akt1 cells, EC50 = 0.46 μM. 16413780
Sf21 cells Function assay Inhibition of JAK3 expressed in Sf21 cells, IC50 = 0.006 μM. 17088059
U937 cells Cytotoxicity assay Cytotoxicity against human U937 cells, IC50 = 2 μM. 17088067
Sf9 cells Function assay 1 min Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP, IC50 = 0.005 μM. 17315853
Sf9 cells Function assay 20 mins Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP, IC50 = 0.015 μM. 17315853
Sf9 cells Function assay 1 min Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP, IC50 = 0.036 μM. 17315853
Sf9 cells Function assay 20 mins Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP, IC50 = 0.083 μM. 17315853
Sf9 cells Function assay 1 min Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP, IC50 = 0.27 μM. 17315853
Sf9 cells Function assay 20 mins Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP, IC50 = 0.51 μM. 17315853
A549 cells Cytotoxicity assay 72 h Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method, GI50 = 0.0024 μM. 18484775
MDA-MB-231 cells Cytotoxicity assay 72 h Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method, GI50 = 0.0071 μM. 18484775
HT29 cells Cytotoxicity assay 72 h Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method, GI50 = 0.0109 μM. 18484775
MCF7 cells Function assay Inhibition of PKA in human MCF7 cells by array-based fluorescence assay, Ki = 0.005 μM. 18656369
MCF7 cells Function assay Inhibition of PKA in human MCF7 cells by array-based fluorescence assay, IC50 = 2 μM. 18656369
Sf9 cells Function assay Inhibition of human Syk expressed in Sf9 cells, IC50 = 0.003 μM. 18823784
Sf9 cells Function assay Inhibition of human ZAP70 expressed in Sf9 cells, IC50 = 0.053 μM. 18823784
insect cells Function assay Inhibition of human recombinant Pim1 expressed in insect cells by HTRF, IC50 = 0.01 μM. 19179076
HT-29 cells Apoptosis assay 2 h Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay, ED50 = 0.0026 μM. 19422206
insect Sf21 cells Function assay Inhibition of JAK3 expressed in insect Sf21 cells assessed as inhibition of biotinylated substrate phosphorylation, IC50 = 0.006 μM. 19427203
Jurkat cells Antiproliferative activity assay Antiproliferative activity against JAK3 expressing IL2-stimulated human Jurkat cells, IC50 = 0.071 μM. 19427203
Jurkat cells Antiproliferative activity assay Antiproliferative activity against JAK3 expressing human resting Jurkat cells, IC50 = 0.311 μM. 19427203
HUE cells Function assay 90 mins Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA, IC50 = 0.07 μM. 20170163
Sf9 cells Function assay 60 mins Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay, IC50 = 2.3 μM. 20580552
Sf21 cells Function assay 30 uM Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM, IC50 = 0.027 μM. 21334796
Sf21 cells Function assay 30 uM Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM, IC50 = 0.039 μM. 21334796
Sf21 cells Function assay 30 uM Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM, IC50 = 0.49 μM. 21334796
HeLa cells Cytotoxicity assay 48 h Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.000004 μM. 21388191
MCF7 cells Cytotoxicity assay 48 h Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 0.05 μM. 21388191
HT-29 cells Function assay 2 h Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay, IC50 = 0.002 μM. 21428375
HeLa cells Cytotoxicity assay 48 h Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.000004 μM. 21488655
MCF7 cells Cytotoxicity assay 48 h Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 0.05 μM. 21488655
HT-29 cells Function assay Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay, IC50 = 0.0025 μM. 21513293
SF268 cells Cytotoxicity assay 48 h Cytotoxicity against human SF268 cells after 48 hrs by SRB assay, GI50 = 0.044 μM. 21513294
CHOK1 cells Cytotoxicity assay 48 h Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay, GI50 = 0.13 μM. 21513294
H460 cells Cytotoxicity assay 48 h Cytotoxicity against human H460 cells after 48 hrs by SRB assay, GI50 = 3.6 μM. 21513294
HT-29 cells Cytotoxicity assay 48 h Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay, GI50 = 3.6 μM. 21513294
MCF7 cells Cytotoxicity assay 48 h Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay, GI50 = 11 μM. 21513294
SW1116 cells Function assay 24 h Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay, IC50 = 8.32 μM. 21962523
HT-29 cells Apoptosis assay 2 h Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay, ED50 = 0.0026 μM. 21973101
LoVo cells Antiproliferative activity assay 48 to 72 h Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay, IC50 = 0.001 μM. 22182929
ST486 cells Antiproliferative activity assay 48 to 72 h Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay, IC50 = 0.007 μM. 22182929
DLD1 cells Antiproliferative activity assay 48 to 72 h Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay, IC50 = 0.009 μM. 22182929
B16F10 cells Antiproliferative activity assay 48 h Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay, IC50 = 2.82 μM. 22503364
MCF7 cells Antiproliferative activity assay 48 h Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 3.07 μM. 22503364
A431 cells Cytotoxicity assay 24 h Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay, IC50 = 0.07 μM. 22541051
MCF7 cells Cytotoxicity assay 24 h Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay, IC50 = 0.18 μM. 22541051
BJ cells Cytotoxicity assay 72 h Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay, IC50 = 0.002 μM. 22921081
CEM cells Cytotoxicity assay 72 h Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay, IC50 = 0.023 μM. 22921081
MCF7 cells Cytotoxicity assay 72 h Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay, IC50 = 0.064 μM. 22921081
HeLa cells Cytotoxicity assay 72 h Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay, IC50 = 0.175 μM. 22921081
HepG2 cells Function assay 24 h Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay, IC50 = 4.14 μM. 23018096
SW1116 cells Antiproliferative activity assay 48 h Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method, IC50 = 4.95 μM. 23018096
HepG2 cells Antiproliferative activity assay 48 h Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method, IC50 = 6.73 μM. 23018096
BGC823 cells Antiproliferative activity assay 48 h Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method, IC50 = 6.83 μM. 23018096
HeLa cells Antiproliferative activity assay 48 h Antiproliferative activity against human HeLa cells after 48 hrs by MTT method, IC50 = 9.12 μM. 23018096
HCT116 cells Function assay Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay, IC50 = 0.039 μM. 23232060
HepG2 cells Function assay 48 h Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA, IC50 = 8.3 μM. 23279864
SW1116 cells Function assay 24 h Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay, IC50 = 4.18 μM. 24286761
KE-97 cells Cytotoxicity assay 72 h Cytotoxicity against human KE-97 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50 = 0.13 μM. 24328283
Jurkat cells Cytotoxicity assay 72 h Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50 = 0.14 μM. 24328283
HuH7 cells Cytotoxicity assay 72 h Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50 = 0.23 μM. 24328283
BGC823 cells Cytotoxicity assay 72 h Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50 = 0.38 μM. 24328283
MCF7 cells Cytotoxicity assay 72 h Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50 = 0.52 μM. 24328283
NIH/3T3 cells Cytotoxicity assay 96 h Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay, IC50 = 0.2 μM. 24361521
A2780 cells Cytotoxicity assay 96 h Cytotoxicity against human A2780 cells after 96 hrs by SRB assay, IC50 = 0.2 μM. 24361521
HT-29 cells Cytotoxicity assay 96 h Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay, IC50 = 0.2 μM. 24361521
8505C cells Cytotoxicity assay 96 h Cytotoxicity against human 8505C cells after 96 hrs by SRB assay, IC50 = 0.2 μM. 24361521
518A2 cells Cytotoxicity assay 96 h Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay, IC50 = 0.2 μM. 24361521
MCF7 cells Cytotoxicity assay 96 h Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay, IC50 = 0.4 μM. 24361521
A549 cells Cytotoxicity assay 96 h Cytotoxicity against human A549 cells after 96 hrs by SRB assay, IC50 = 0.6 μM. 24361521
V79 MZ cells Function assay Inhibition of human aldosterone synthase expressed in V79 MZ cells assessed as inhibition of aldosterone synthesis, IC50 = 0.011 μM. 24422519
HEK293 cells Cytotoxicity assay 72 h Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay, IC50 = 0.056 μM. 24763262
HeLa cells Antiproliferative activity assay 24 to 48 h Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay, IC50 = 2.72 μM. 24792811
A549 cells Antiproliferative activity assay 24 to 48 h Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay, IC50 = 3.05 μM. 24792811
HepG2 cells Cytotoxicity assay Cytotoxicity against human HepG2 cells, EC50 = 2 μM. 25316317
Raji cells Cytotoxicity assay Cytotoxicity against human Raji cells, EC50 = 2 μM. 25316317
BJ cells Cytotoxicity assay Cytotoxicity against human BJ cells, EC50 = 2 μM. 25316317
HEK293 cells Cytotoxicity assay Cytotoxicity against HEK293 cells, EC50 = 2 μM. 25316317
A549 cells Cytotoxicity assay 48 h Cytotoxicity against human A549 cells after 48 hrs by MTT assay, IC50 = 0.02 μM. 25825934
HeLa cells Cytotoxicity assay 48 h Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.025 μM. 25825934
PC3 cells Cytotoxicity assay 48 h Cytotoxicity against human PC3 cells after 48 hrs by MTT assay, IC50 = 0.031 μM. 25825934
MGC-803 cells Function assay 24 h Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay, IC50 = 8.97 μM. 26900656
Sf9 insect cells Function assay 10 mins Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay, IC50 = 0.0012 μM. 27089211
Sf21 cells Function assay 60 mins Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method, IC50 = 0.002 μM. 27137359
Neuro2a cells Cytotoxicity assay 72 h Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay, IC50 = 0.0113 μM. 28152427
MDA-MB-231 cells Function assay 16 h Inhibition of retinoblastoma protein phosphorylation in human MDA-MB-231 cells after 16 hrs by Hoechst 33342 staining based fluorescence assay, IC50 = 0.066 μM. 28431342
Sf9 insect cells Function assay 20 mins Inhibition of recombinant human N-terminally GST-tagged EGFR L858R/T790M/C797S triple mutant expressed in baculovirus in Sf9 insect cells preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method, IC50 = 0.00029 μM. 28482151
HEK293 cells Cytotoxicity assay 72 h Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay, CC50 = 0.00354 μM. 28624701
BT549 cells Cytotoxicity assay 24 h Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay, IC50 = 0.08 μM. 28705432
MDA-MB-468 cells Cytotoxicity assay 24 h Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay, IC50 = 0.15 μM. 28705432
MDA-MB-231 cells Cytotoxicity assay 24 h Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay, IC50 = 0.24 μM. 28705432
Vero cells Cytotoxicity assay 2 days Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 2 days by cell-titer-glo luminescent assay, TC50 = 0.0024 μM. 28763645
L929 cells Antiproliferative activity assay 5 days Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay, IC50 = 0.2 μM. 28956915
KB-3-1 cells Antiproliferative activity assay 5 days Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay, IC50 = 0.2 μM. 28956915
MCF7 cells Antiproliferative activity assay 5 days Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay, IC50 = 1.8 μM. 28956915
FS4-LTM cells Antiproliferative activity assay 24 h Antiproliferative activity against human FS4-LTM cells after 24 hrs by WST-1 assay, IC50 = 2.8 μM. 28956915
Vero cells Cytotoxicity assay 2 days Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay, IC50 = 0.0024 μM. 28993106
HepG2 cells Cytotoxicity assay 100 uM 3 days Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay, IC50 = 0.018 μM. 28993106
NIH/3T3 cells Cytotoxicity assay 96 h Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay, EC50 = 0.008 μM. 29197730
518A2 cells Cytotoxicity assay 96 h Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay, EC50 = 0.03 μM. 29197730
A549 cells Cytotoxicity assay 96 h Cytotoxicity against human A549 cells after 96 hrs by SRB assay, EC50 = 0.04 μM. 29197730
MCF7 cells Cytotoxicity assay 96 h Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay, EC50 = 0.1 μM. 29197730
A2780 cells Cytotoxicity assay 96 h Cytotoxicity against human A2780 cells after 96 hrs by SRB assay, EC50 = 0.12 μM. 29197730
HT-29 cells Cytotoxicity assay 96 h Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay, EC50 = 0.15 μM. 29197730
PC3 cells Cytotoxicity assay Cytotoxicity against human PC3 cells by sulforhodamine B assay, IC50 = 0.017 μM. 29389122
HCT116 cells Cytotoxicity assay Cytotoxicity against human HCT116 cells by sulforhodamine B assay, IC50 = 0.055 μM. 29389122
insect cells Function assay 30 mins Inhibition of recombinant human PDGFRbeta expressed in insect cells using Ulight-Poly GAT[EAY(1:1:1)]n as substrate after 30 mins by LANCE method, IC50 = 0.00076 μM. 29549836
Sf9 insect cells Function assay 60 mins Inhibition of recombinant human KDR expressed in Sf9 insect cells using Ulight-CAGAGAIETDKEYYTVKD as substrate after 60 mins by LANCE method, IC50 = 0.0021 μM. 29549836
insect cells Function assay 10 mins Inhibition of recombinant human Src expressed in insect cells using Ulight-Poly GAT[EAY(1:1:1)]n as substrate after 10 mins by LANCE method, IC50 = 0.005 μM. 29549836
insect cells Function assay 15 mins Inhibition of recombinant human CDK1/Cyclin B expressed in insect cells using Ulight-CFFKNIVTPRTPPPSQGK-amide as substrate after 15 mins by LANCE method, IC50 = 0.025 μM. 29549836
insect cells Function assay 15 mins Inhibition of recombinant human CDK1/Cyclin B expressed in insect cells using Ulight-CFFKNIVTPRTPPPSQGK-amide as substrate after 15 mins by LANCE method, IC50 = 0.025 μM. 29549836
Sf9 insect cells Function assay 15 mins Inhibition of recombinant human Flt1 expressed in Sf9 insect cells using Ulight-TK peptide as substrate after 15 mins by LANCE method, IC50 = 0.035 μM. 29549836
Sf21 insect cells Function assay 15 mins Inhibition of recombinant human Aurora-A expressed in Sf21 insect cells using Ulight-RRRSLLE as substrate after 15 mins by LANCE method, IC50 = 0.039 μM. 29549836
insect cells Function assay 60 mins Inhibition of recombinant human AKT1 expressed in insect cells using CREBtide as substrate after 60 mins by LANCE method, IC50 = 0.056 μM. 29549836
Sf9 insect cells Function assay 60 mins Inhibition of recombinant human FAK expressed in Sf9 insect cells using Ulight-TK peptide as substrate after 60 mins by LANCE method, IC50 = 0.062 μM. 29549836
insect cells Function assay 60 mins Inhibition of recombinant human ABL expressed in insect cells using Ulight-TK peptide as substrate after 60 mins by LANCE method, IC50 = 0.29 μM. 29549836
insect cells Function assay 60 mins Inhibition of recombinant human c-MET expressed in insect cells using Ulight-CAGAGAIETDKEYYTVKD as substrate after 60 mins by LANCE method, IC50 = 0.31 μM. 29549836
PC3 cells Cytotoxicity assay 72 h Cytotoxicity against human PC3 cells after 72 hrs by SRB assay, IC50 = 0.039 μM. 29558119
Sf9 cells Function assay 45 mins Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay, IC50 = 0.047 μM. 29902719
Sf9 cells Function assay 45 mins Inhibition of recombinant human N-terminal GST-tagged HER2 (679 to 1255 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay, IC50 = 0.0608 μM. 29902719
HT-29 cells Function assay 3 h Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay, IC50 = 0.02 μM. 30057155
Sf9 cells Function assay Inhibition of N-terminal FLAG-tagged human full-length CDK12 (1 to 1490 residues)/N-terminal His-tagged CycK (1 to 580 residues) expressed in Sf9 cells assessed as reduction in ATP-dependent ULight-4E-BP1 (Thr37/Thr46) substrate peptide phosphorylation pr, IC50 = 0.053 μM. 30067358
Sf9 cells Function assay Inhibition of N-terminal FLAG-tagged human full-length CDK12 (1 to 1490 residues)/N-terminal His-tagged CycK (1 to 580 residues) expressed in Sf9 cells assessed as reduction in ATP-dependent ULight-4E-BP1 (Thr37/Thr46) substrate peptide phosphorylation pr, IC50 = 0.053 μM. 30067358
Sf9 cells Function assay Inhibition of N-terminal FLAG-tagged human full-length CDK13 (1 to 1512 residues)/N-terminal His-tagged CycK (1 to 580 residues) expressed in Sf9 cells assessed as reduction in ATP-dependent ULight-4E-BP1 (Thr37/Thr46) substrate peptide phosphorylation pr, IC50 = 0.057 μM. 30067358
Sf9 cells Function assay Inhibition of N-terminal FLAG-tagged human full-length CDK13 (1 to 1512 residues)/N-terminal His-tagged CycK (1 to 580 residues) expressed in Sf9 cells assessed as reduction in ATP-dependent ULight-4E-BP1 (Thr37/Thr46) substrate peptide phosphorylation pr, IC50 = 0.057 μM. 30067358
HCT116 cells Cytotoxicity assay 48 h Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 0.03 μM. 30106291
Huh7.5 cells Cytotoxicity assay 48 h Cytotoxicity against human Huh7.5 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 0.6 μM. 30106291
K562 cells Cytotoxicity assay 48 h Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 1.7 μM. 30106291
LO2 cells Cytotoxicity assay 48 h Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 9.5 μM. 30106291
Cliquez pour voir plus de données expérimentales sur les lignées cellulaires

Informations chimiques, stockage et stabilité

Poids moléculaire 466.53 Formule

C28H26N4O3

Stockage (À partir de la date de réception)
N° CAS 62996-74-1 Télécharger le SDF Stockage des solutions mères

Synonymes AM-2282,Antibiotic AM-2282 Smiles CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC

Solubilité

In vitro
Lot:

DMSO : 46 mg/mL (98.6 mM)
(Le DMSO contaminé par lhumidité peut réduire la solubilité. Utiliser du DMSO frais et anhydre.)

Water : Insoluble

Ethanol : Insoluble

Calculateur de molarité

Masse Concentration Volume Poids moléculaire
Calculateur de dilution Calculateur de poids moléculaire

In vivo
Lot:

Calculateur de formulation in vivo (Solution claire)

Étape 1 : Entrez les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant lexpérience)

mg/kg g μL

Étape 2 : Entrez la formulation in vivo (Ceci nest que le calculateur, pas la formulation. Veuillez nous contacter dabord sil ny a pas de formulation in vivo dans la section Solubilité.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Résultats du calcul :

Concentration de travail : mg/ml;

Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter dabord si la concentration dépasse la solubilité du DMSO du lot de médicament. )

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, ajouter ensuiteμL PEG300, mélanger et clarifier, ajouter ensuiteμL Tween 80, mélanger et clarifier, ajouter ensuite μL ddH2O, mélanger et clarifier.

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, ajouter ensuite μL Huile de maïs, mélanger et clarifier.

Remarque : 1. Assurez-vous que le liquide est clair avant dajouter le solvant suivant.
2. Assurez-vous dajouter le(s) solvant(s) dans lordre. Vous devez vous assurer que la solution obtenue lors de lajout précédent est une solution claire avant de procéder à lajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie peuvent être utilisées pour faciliter la dissolution.

Mécanisme daction

Targets/IC50/Ki
PKCα
(Cell-free assay)
2 nM
c-Fgr
(Cell-free assay)
2 nM
phosphorylase kinase
(Cell-free assay)
3 nM
PKCη
(Cell-free assay)
4 nM
PKCγ
(Cell-free assay)
5 nM
S6 kinase
(Cell-free assay)
5 nM
v-Src
(Cell-free assay)
6 nM
Cdc2
(Cell-free assay)
9 nM
Cdc2
(Cell-free assay)
9 nM
PKA
(Cell-free assay)
15 nM
Syk
(Cell-free assay)
16 nM
PKG
(Cell-free assay)
18 nM
PKCδ
(Cell-free assay)
20 nM
CaMKII
(Cell-free assay)
20 nM
Lyn
(Cell-free assay)
20 nM
MLCK
(Cell-free assay)
21 nM
PKCε
(Cell-free assay)
73 nM
In vitro
Staurosporine (STS), un alcaloïde microbien, inhibe significativement la protéine kinase C du cerveau de rat avec une IC50 de 2,7 nM. Il affiche également un fort effet inhibiteur contre les cellules HeLa S3 avec une IC50 de 4 nM. Ce composé inhibe une variété d'autres protéines kinases, y compris PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, et Syk avec des IC50 de respectivement 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM et 16 nM. À 1 μM, il induit >90% d'apoptose dans les cellules PC12. De manière cohérente, ce traitement induit une élévation rapide et prolongée des niveaux de calcium libre intracellulaire [Ca2+]i, une accumulation d'espèces réactives de l'oxygène (ROS) mitochondriales, et une dysfonction mitochondriale subséquente. L'apoptose des cellules MCF7 induite par STS peut être améliorée par l'expression de la caspase-3 fonctionnelle via l'activation de la caspase-8 et le clivage de Bid. Le traitement à 1 μM n'inhibe que partiellement la phosphorylation de Bcl2 stimulée par IL-3 mais bloque complètement la phosphorylation de Bcl2 médiée par PKC. Il induit l'apoptose des fibroblastes de prépuce humain AG-1518, dépendamment de la libération du cytochrome c médiée par les cathepsines D lysosomales et l'activation des caspases. En plus d'activer la voie classique de l'apoptose mitochondriale, STS déclenche une nouvelle voie intrinsèque d'apoptose, reposant sur l'activation de la caspase-9 en l'absence d'Apaf-1.
Kinase Assay
Essai enzymatique et essai de liaison
La protéine kinase C est testée dans un mélange réactionnel (0,25 mL) contenant 5 μmol de Tris/HCl, pH 7,5, 2,5 μmol d'acétate de magnésium, 50 μg d'histone II S, 20 μg de phosphatidylsérine, 0,88 μg de dioléine, 125 nmol de CaCl2, 1,25 nmol de [γ-32]ATP (5-10 × 104 cpm/nmol) et 5 μg d'enzyme partiellement purifiée. La liaison de [3H]PDBu à la protéine kinase C est déterminée : Le mélange réactionnel (200 μL) contenait 4 μmol de Tris/malate, pH 6,8, 20 μmol de KCl, 30 nmol de CaCl2, 20 μg de phosphatidylsérine, 5 μg de protéine kinase C partiellement purifiée, 0,5% (concentration finale) de DMSO, 10 pmol de [3H]PDBu (1-3 × 104 cpm/pmol) et 10 μL de diverses quantités de Staurosporine (STS).
In vivo
Dans les modèles d'ischémie chez le gerbille et le rat, le prétraitement avec Staurosporine (STS) (0,1–10 ng) avant l'ischémie prévient les dommages neuronaux de manière dose-dépendante, suggérant l'implication de PKC dans la mort des cellules pyramidales CA1 après l'ischémie.
Références
  • [4] https://pubmed.ncbi.nlm.nih.gov/10734071/
  • [5] https://pubmed.ncbi.nlm.nih.gov/10677502/
  • [6] https://pubmed.ncbi.nlm.nih.gov/14576777/
  • [7] https://pubmed.ncbi.nlm.nih.gov/21659556/
  • [8] https://pubmed.ncbi.nlm.nih.gov/2384538/

Applications

Méthodes Biomarqueurs Images PMID
Western blot p-Akt / Akt / PARP /Cleaved PARP FAK / RIP Ambra1
S1421-WB1
24174874
Growth inhibition assay Cell viability
S1421-viability
25215174
Immunofluorescence Tubulin / Actin Phalloidin / Type II collagen Pyk2 Annexin cleaved-caspase 3 FAK 4.47
S1421-IF2
25215174

Informations sur lessai clinique

(données de https://clinicaltrials.gov, mis à jour le 2024-05-22)

Numéro NCT Recrutement Conditions Sponsor/Collaborateurs Date de début Phases
NCT05209347 Withdrawn
Ankle Fractures|Post-traumatic Osteoarthritis|Osteoarthritis Ankle
University of Iowa
December 2024 Not Applicable
NCT05956990 Not yet recruiting
Colorectal Cancer Survivor|Rehabilitation|Quality of Life
Qu Shen|The First Affiliated Hospital of Xiamen University|Xiamen University
July 1 2024 Not Applicable
NCT05957289 Not yet recruiting
Rehabilitation|Colorectal Cancer Survivor|Quality of Life|Pilot Study
Qu Shen|The First Affiliated Hospital of Xiamen University|Xiamen University
June 1 2024 Not Applicable
NCT06245135 Not yet recruiting
Mobility Limitation
University of Toronto|University Health Network Toronto|March of Dimes Canada|Heart and Stroke Foundation of Canada|University of Alberta|University of Manitoba|Bruyere Research Institute
June 2024 Not Applicable
NCT06374108 Not yet recruiting
Multiple Sclerosis
University of Aarhus|Aarhus University Hospital|University of Copenhagen
May 1 2024 Not Applicable

Support technique

Instructions de manipulation

Tel: +1-832-582-8158 Ext:3

Si vous avez dautres questions, veuillez laisser un message.

Veuillez entrer votre nom.
Veuillez entrer votre e-mail. Veuillez entrer une adresse e-mail valide.
Veuillez nous écrire quelque chose.